Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Assets (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Other Non-Current Assets for 14 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $3.4 million, compared with a TTM value of $3.4 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $3.4 million, up 3474.47% over the prior year.
  • Other Non-Current Assets was $3.4 million for Q4 2025 at Enanta Pharmaceuticals, roughly flat from $3.4 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $4.0 million in Q4 2022 and bottomed at $92000.0 in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $1.6 million, with a median of $699500.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Assets skyrocketed 4213.04% in 2022, then crashed 97.53% in 2025.
  • Year by year, Other Non-Current Assets stood at $92000.0 in 2021, then surged by 4213.04% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then fell by 15.32% to $3.4 million in 2024, then changed by 0.0% to $3.4 million in 2025.
  • Business Quant data shows Other Non-Current Assets for ENTA at $3.4 million in Q4 2025, $3.4 million in Q3 2025, and $94000.0 in Q2 2025.